Virology and liver disease treatment company Bluejay Therapeutics has raised $41 million in series B funding.
Bluejay Therapeutics has two product lines focused on the detection and care of hepatitis B. The funding from this round will go to support the clinical development of these drugs, according to the Aug. 16 Bluejay Therapeutics news release.
The series B funding round was led by Arkin Bio Ventures. Alon Lazarus, PhD, an investment manager at Arkin Bio Ventures, will join the Bluejay Therapeutics board of directors.